Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma – The New England Journal of Medicine

Conteudo completo do artigo

Are you a member of an institution such as a university or hospital? Learn more about Institutional Access Select the format you want to export the citation of this publication. Already have an account? Sign In Interested in purchasing this article?

BUY NOW FOR $55 Yiling Liu, Matthew L. Pawlush, Justyna J. Gleba, Ella G. Lambert, Caitlin E. Williams, Martina H. Stenzel, John A. Copland, Kristopher A. Kilian, Hydrogel microtumor arrays of patient melanoma recapitulate phenotypes and drug sensitivity, Biomaterials Advances, 188, (215015), (2026). https: //doi. org/10.1016/j. bioadv. 2026.215015Crossref Rashidul Alam Mahumud, Cost-effectiveness and budget impact analysis of pembrolizumab as an adjuvant treatment of resected stage III melanoma from an Australian healthcare system perspective, Journal of Cancer Policy, 49, (100760), (2026). https: //doi. org/10.1016/j. jcpo. 2026.100760Crossref Théo Erard, Gaelle Quéreux, Mona Amini-Adle, Henri Montaudié, Julie Charles, Marc Puyraveau, Géraldine Jeudy, Philippe Bernard, Florent Grange, Delphine Legoupil, Ouidad Zehou, Philippe Celerier, Candice Lesage, Amir Khammari, François Aubin, Charlée Nardin, Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS), European Journal of Cancer, 244, (116878), (2026). https: //doi. org/10.1016/j. ejca. 2026.116878Crossref Markus Reitmajer, Elisabeth Livingstone, Lucie Heinzerling, Kai‐Martin Thoms, Frank Meiss, Markus V. Heppt, Anja Gesierich, Konstantin Drexler, Friedegund Meier, Max Schlaak, Andrea Forschner, Lisa Zimmer, Adjuvante Systemtherapie beim Melanom in der Praxis: Multizentrische Erhebung an 51 DeCOG‐Hautkrebszentren, JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 24,7, (916-927), (2026). https: //doi. org/10.1111/ddg. 15963_gCrossref Julien Edeline, Ming Kuang, Maria Reig, Valérie Vilgrain, Integrating systemic therapy in the earlier stages of liver cancer, Journal of Hepatology, (2026). https: //doi. org/10.1016/j. jhep. 2026.03.024Crossref Francis Proulx-Rocray, Rebecca Symons, Yang Wang, Samrin Liaqat, Lydia Warburton, Claresta Jiang, Terence Wong, Edward Hsiao, Sydney Ch'ng, Kerwin F. Shannon, Michael Rtshiladze, Thomas E. Pennington, David J. Coker, Matteo S. Carlino, Andrew Spillane, Jonathan Stretch, Robyn P. M. Saw, Alexander C. J. van Akkooi, Hayden Snow, David E. Gyorki, Lavinia Spain, Louise A. Jackett, Victoria Atkinson, Rachel Roberts-Thomson, Marcin Dzienis, Adnan Khattak, Shahneen Sandhu, Robert V. Rawson, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies, Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma – The early Australian experience, European Journal of Cancer, 243, (116865), (2026). https: //doi. org/10.1016/j. ejca. 2026.116865Crossref Han Wang, Ran Zhang, Li Zhou, Qian Liang, Hong Ma, Xiaomei Nie, Gang Su, Case Report: Vogt-Koyanagi-Harada-like uveitis associated with combined dabrafenib/trametinib and cadonilimab therapy for cutaneous melanoma, Frontiers in Medicine, 13, (2026). https: //doi. org/10.3389/fmed. 2026.1804008Crossref Daniel Goldshtein, Yousuf Shad, Elaine McWhirter, Richard Tozer, Adi Kartolo, Meaningful efficacy measures and trial endpoints in patients with advanced melanoma being considered for adjuvant systemic therapy: a prospective patient survey study, Melanoma Research, 36,4, (321-327), (2026). https: //doi. org/10.1097/CMR. 0000000000001114Crossref Marcella Scala, David Lorente-Estellés, Luigi Liguori, María José Juan-Fita, Emanuela De Nicola, Zaida García-Casado, Victor Traves, Ruggero Moro, Celia Requena, Rajiv Kumar, Luigi Formisano, Eduardo Nagore, Melanocortin-1 receptor variants and telomerase reverse transcriptase promoter mutations as prognostic biomarkers in stage IIB–IIC melanoma, Melanoma Research, 36,4, (286-295), (2026). https: //doi. org/10.1097/CMR. 0000000000001113Crossref Isabel Hariri, Jessica C. Hassel, Therapie des Melanoms, Die Pathologie, (2026). https: //doi. org/10.1007/s00292-026-01575-6Crossref